Skip to main content

Table 1 Baseline characteristics of the participants

From: Optimization of osteoporosis and osteopenia management among renal transplant recipients

Parameter (reference)

Denosumab

(n = 52)

Ibandronate

(n = 48)

P value

Gender (male/female)

24/28

21/27

0.80a

Age

56.08 (± 14)

53.32 (± 13)

0.54a

Osteopenia/ Osteoporosis patients

40/12

37/11

0.98a

Time after Transplant (months)

24.9 (± 13.85)

25.46 (± 14.18)

0.84a

Body Mass Index (kg/m2)

29.9 (± 5.2)

29.6 (± 4.6)

0.71a

Vitamin D (75–250 nmol/L)

63.52 (± 8.1)

55.07 (± 9.7)

0.15a

Calcium (2.2–2.5 mmol/L)

2.33 (± 0.17)

2.35 (± 14)

0.19a

Phosphorous (0.8–1.5 mmol/L)

1.18 (± 0.15)

1.17 (± 0.26)

0.69a

Serum creatinine (40–115 µmol/L)

105.4 (± 29.45)

109.6 (± 28.68)

0.07a

Urea (2.5–6.4 mmol/L)

5.95 (± 2.5)

5.35 (± 2.89)

0.32a

Sodium (135–145 mmol/L)

138.25 (± 3.23)

138.82 (± 4.07)

0.77a

Chloride (98–107 mmol/L)

103.86 (± 2.95)

103.2 (± 3.63)

0.88a

Uric acid (208–425 µmol/L)

364.75 (± 79)

372.69 (± 65)

0.17a

Total Cumulative Steroid (gm)

1.58 (± 0.25)

1.51 (± 0.30)

0.48a

T-score

 Spinal Osteoporosis

−3.13 (± 0.6)

−2.80 (± 0.3)

0.26a

 Spinal Osteopenia

−1.9 (± 0.27)

−1.6 (± 0.15)

0.44a

 Hip Osteoporosis

−3.45 (± 0.4)

−3.1 (± 0.6)

0.94a

 Hip Osteopenia

−1.5 (± 0.2)

−1.4 (± 0.23)

0.94a

Immunosuppression

 Predinsolone

52 (100%)

48 (100%)

 Mycophenolate

52 (100%)

48 (100%)

 Tacrolimus

42 (80%)

36 (75%)

 

 Cyclosporine

10 (20%)

12 (25%)

0.49a

  1. Data are presented at baseline as number only, mean ± standard deviation, or percentages only
  2. Categorical data are presented as percentages and were compared using the chi-squared test, while the Student T-test was used for normally distributed variables; significance was found at P ≤ 0.05
  3. aNonsignificant difference between the two groups